Advertisement

BMC Research Notes

, 12:216 | Cite as

Effects of vitamin D3 and its chemical analogs on the growth of Hodgkin’s lymphoma, in vitro

  • Rajendra GharbaranEmail author
  • Bo Zhang
  • Luis Valerio
  • Onyekwere Onwumere
  • Madeline Wong
  • Jason Mighty
  • Stephen Redenti
Open Access
Research note

Abstract

Objective

Vitamin D receptor (VDR) activities have been noted for a number of B cell malignancies which showed varying sensitivities to vitamin D3 (1,25-dihydroxyvitamin D3, VD3, calcitriol) and its synthetic analogs. The objective of this study was to address the potential effects of VD3 and vitamin D3 analogs (VDAs) on the growth of Hodgkin’s lymphoma (HL), a malignant pathology of B cell origin, in vitro.

Results

Immunofluorescence staining showed the expression of VDR by primary Hodgkin’s (H) and Reed–Sternberg (RS)—HRS-tumor cells in HL histological sections. Western blot analyses revealed expression of VDR in the HL cell lines Hs445, HDLM2, KMH2, and L428. One-way analysis of variance (ANOVA) on data obtained from water-soluble tetrazolium 1 (WST-1) cell proliferation assay showed decreased cell growth in HDLM2 and L428, 72 h after treatment with 10 µM of either VD3 of VDAs. Western blot analyses showed that treatment of L428 cells with the VDAs (calcipotriol and EB1089) resulted in modest increases in nuclear accumulation of VDR (nuVDR) compared to either dimethyl sulfoxide (DMSO) or VD3 treatments. nuVDR for DMSO control and VD3 was comparable. These results suggest that VD3 or VDAs may affect growth of HL.

Keywords

Vitamin D3 Hodgkin’s lymphoma Cancer Oncology Calcitriol EB1089 Calcipotriol B cell malignancy 

Abbreviations

VDR

vitamin D receptor

VD3

vitamin D3

VDA

vitamin D3 analogs

HL

Hodgkin’s lymphoma

H

Hodgkin

RS

Reed–Sternberg

HRS

Hodgkin’s and Reed Sternberg

ANOVA

analysis of variance

nuVDR

nuclear accumulation of vitamin D receptor

DMSO

dimethyl sulfoxide

WST-1

water-soluble tetrazolium 1

EFS

event-free survival

OS

overall survival

FBS

fetal bovine serum

TBS

tris buffered saline

RIPA

radioimmunoprecipitation

SDS-PAGE

sodium dodysulfate polyacrylamide gel

BSA

bovine serum albumin

SEM

standard error of the mean

Introduction

Vitamin D3 receptor signaling and its therapeutic perturbation with vitamin D3 (VD3, 1,25-dihydroxyvitamin, calcitriol) or vitamin D3 analogs (VDAs) have attracted much attention in cancer therapies, including treatment of B cell malignancies [1]. This is largely due to reports that showed strong association between VD3 deficiency and increased risk of both solid and liquid tumors [2, 3, 4, 5]. In subsets of B cell malignancies, low vitamin D is associated with worst prognosis—inferior event-free survival (EFS) and overall survival (OS) [2]. Studies showed that upon ligand (either VD3 or VDA) binding, VDR translocates to the nucleus where it modulates the expression of genes involved in cell growth and differentiation and apoptosis [6].

Hodgkin’s lymphoma (HL) is presented as a unique B cell neoplasm characterized by the presence of giant mononuclear Hodgkin’s (H) and multinuclear Reed–Sternberg (RS)—HRS-cells, which make up less than 1% of the cellular infiltrate of the tumor microenvironment. Although a previous immunohistochemical study showed that VDR is highly expressed in 80% of HL cases [7], very little is known about the influence of VD3/VDA–VDR interaction in this malignancy. Therefore, the goal of the current study was to investigate the effects of VD3/VDAs on the growth of HL via VDR expression, in vitro.

Main text

Methods and materials

Immunofluorescence

Immunofluorescence was performed as described by Gharbaran et al. [8] with some modifications. Tissue array (US Biomax) consisting of 5-μm thick formaldehyde-fixed paraffin-embed histological sections was dewaxed with 2× with xylene (10 min each), rehydrated in 100, 80, 70, 50% ethanol (5 min each), and rinsed briefly in 1× PBS. Antigen retrieval was performed by heating sections for 20 min in 10 mM Na citrate (pH 6.0) at 95 °C followed by cooling for 20 min at room temperature. Sections were subsequently blocked with BSA (5% in Tris buffered saline (TBS, Sigma) then incubated overnight with anti-VDR mouse monoclonal antibody (Santa cruz; sc-13133) diluted at 1:100 in blocking buffer, at 4 °C. The tissue array was next washed 3× in TBS for 5 min each. This was followed by incubation in Dylight 594-conjugated mouse secondary antibody (Jackson Immunoresearch) diluted at 1:500 in blocking buffer, in the dark for 1 h at room temperature, subsequent washes as described. The sections were covered with number 1 coverslips containing 10 µL of mounting medium containing DAPI (Vector Labs). Staining was visualized on a Nikon Ti Eclipse inverted microscope. Images were captured with a CoolSNAP HQ2 CCD camera (Photometric Scientific) coupled to the microscope and processed with Adobe Photoshop 7.0 (Adobe, San Jose, CA) for clarity. All steps were same for negative controls with the exception of incubation in primary antibody.

Cell lines and cell cultures

The human HRS-derived cell lines HDLM2, KMH2 and L428 were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ), Department of Human and Animal Cell Cultures, Braunschweig, Germany. Hs445 was obtained from the American Tissue and Cell Collection (ATCC). L428 and KMH2 were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco BRL, Gaithersburg, MD), 1% l-glutamine, and penicillin/streptomycin. Culture media for HDLM2 and Hs445 were similar but contained 20% heat-inactivated FBS. All cells were maintained in a humid environment of 5% CO2 at 37 °C.

Vitamin D3 and its chemical analogs

VD3 or VDAs (calcipotriol and EB1089) were purchased from Cayman Chemicals and dissolved in DMSO to prepare a 10 mM stock which was aliquoted and stored at − 20 °C until ready to be used.

WST-1 cell proliferation assay

2 × 105 cells/mL plated in 96-well plates overnight and treated with 10 μM each of VD3, calcipotriol, and EB1089 for 72 h were incubated in indicated culture conditions. Cell growth was assessed with WST-1 cell proliferation assay (Roche, USA), according to manufacturer’s instructions. In brief, 100 μL of treated cells were incubated with 10 µL of WST-1 reagent for 3 h following standard culture conditions. Absorbance was read at 450 nm on a Synergy H1 Hybrid microplate reader (BioTek). Cell growth (in percentages, %) was computed as ratio of absorbance (A450 nm) of treated cells relative to absorbance of control cells (DMSO) (A450 nm).

Preparation of nuclear extracts

L428 was plated at 1.5 × 105 cells/mL in 60-mm petri and incubated overnight. Cells were then treated with 10 μM each of VD3 or VDAs or vehicle (DMSO) and incubated for another 48 h. Treated cells were harvested by centrifugation for 5 min at 300×g, then washed 2× with ice-cold 1× PBS. Cell membrane was lysed by resuspending the cells in 500 μL ice-cold hypotonic buffer (20 mM Tris–HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2) supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (Thermofisher) and incubated on ice for 15 min, with occasional mixing. The lysate was then mixed with 25 μL of 10% NP4O by vortexing for 10 s. The homogenate was centrifuged at 3000 rpm for 10 min at 4 °C. Supernatant was transferred to a new tube and mix with RIPA (radioimmunoprecipitation) assay buffer (EMD Millipore) supplemented with protease and phosphatase inhibitor as described. Pellet (nuclear fraction) was resuspended in 150 μL ice-cold 1× RIPA buffer as described and incubated on ice, with vortexing at 10 min interval. Nuclear fraction was subsequently centrifuged for 30 min at 14,000×g at 4 °C and the supernatant aliquoted and stored at − 80 °C until ready for quantification by Bradford assay and analysis by sodium dodysulfate polyacrylamide (SDS-PAGE) gel and Western blot.

Preparation of total cell extracts

Treated cells were collected and rinse as described, then resuspended in ice-cold RIPA buffer supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific, Rockford, IL, USA). Lysates were incubated for 5 min on ice with periodic mixing followed by centrifugation at 13,000×g for 10 min at 4 °C. Supernatant was transferred to new tube and stored at − 80 °C until ready for quantification by Bradford assay and SDS-PAGE and Western blot analyses.

Western blot

Protein concentrations were determined using Pierce® BCA Protein Assay kit (Thermo Scientific) following the manufacturer’s instructions. Twenty micrograms of protein were then loaded per well. Proteins were separated on 10% SDS-PAGE and transferred to nitrocellulose membrane (Odyssey 0.22 µm) using Bio-Rad Mini-PROTEAN Electrophoresis System. The membrane was incubated overnight with the primary antibodies at the indicated dilution prepared in TBST containing 2% BSA: anti-VDR (Santa Cruz; sc-13133, 1:1000), anti-histone (Invitrogen; 24HC2, 1:2000), anti-α-tubulin (Sigma; T6074, 1:2000). After brief rinses with TBST, the membrane was incubated with IRDye® 680RD Donkey anti-Mouse (LI-COR, 926-68072), and IRDye® 800CW Donkey anti-Rabbit (LI-COR, 926-32213) for 30 min. Membrane was finally rinsed as described and protein signal was imaged using Odyssey-CLX imaging system (Li-COR).

Statistical analyses

Data analyses were performed using SAS 9.1.3, StatView 5, or JMP 4. Absorbance data reflection cell growth were presented as standard error of the mean (SEM) derived from triplicates. Analysis of variance (ANOVA) and F statistics were used to determine differences between the means as defined by p < 0.05. All experiments were repeated at least three times.

Results

Expression of VDR

The physiological responses of VD3/VDAs are mediated via VDR. Therefore, we analyze HL tissue sections and cell lines for the expression of VDR. Our immunofluorescence staining showed the expression of VDR by HRS cells on tissue array (Fig. 1a). This observation is consistent with a previous immunohistochemical study which showed that VDR is expressed by almost 80% of HL cases [7]. VDR expression by HL cell lines was determined by Western blot analyses. Hs445, HDLM2, KMH2, and L428 showed relatively low expression but varying levels of VDR (Fig. 1b).
Fig. 1

Detection of VDR expression in HL. a Tissue immunofluorescence staining showing the expression of VDR (red) in primary tumor cells of Hodgkin’s lymphoma, Hodgkin’s and Reed–Sternberg (HRS) cells. Nuclei of cells are stained with DAPI. Arrows indicate representative HRS cells. Scale bar = 100 μm. b Detection of VDR expression by Western blot in unstimulated HL cell lines. Arrow indicates VDR band. Histone was used as the house keeping protein

Effects of VD analogs on cell growth

Previous studies indicated growth-limiting activities of VD3/VDAs on both normal and malignant B lymphoid cells [9]. Therefore, we next studied the effects of VD3 and the VDAs calcipotriol and EB1089 on the growth of HL cells HDLM2 and L428. One-way ANOVA on data obtained from WST-1 cell proliferation assay revealed decreases in growth of cells treated with either VD3 or VDAs, after 72 h (Fig. 2). As expected, EB1089 showed a greater effect in reducing growth of both HDLM2 and L428.
Fig. 2

Effects of VD3 and VDAs on growth of Hodgkin’s lymphoma. L428 and HDLM2 cells treated with 10 μM of either VD3 or VDAs (calcipotriol and EB1089) for 72 h showed modest decrease in growth. EB1089 showed the strongest effect

Nuclear accumulation

It has been suggested that upon ligand (VD3/VDAs) binding, VDR translocates to the nucleus where it modulates the expression of target genes. Therefore, we tested the effects of VD3/VDAs on the nuclear accumulation of VDR by Western blot. L428 cells treated with 10 µM of VDAs for 48 h showed only a modest increase in nuVDR over either DMSO- or VD3-treated cells (DMSO and VD3 showed comparable effects on nuVDR)—Fig. 3. The modest changes in nuVDR in our study may be due to very low basal levels of VDR in unstimulated L428 cells.
Fig. 3

Nuclear accumulation of VDR in L428 after treatment with VD3/VDAs for 48 h. EB1089 and calcipotriol resulted in greater nuVDR. DMSO and VD3 showed comparable levels of nuVDR. α-tubulin was used as the housekeeping protein

Discussion

Our data showed that VDR is expressed by HL cell lines and primary HRS cells. The HL cell lines used in this study showed low but varying levels of VDR expression. Also, expression of VDR by HRS cells is qualitatively in accordance with the study by Renne et al. [7]. The results also showed that VD3/VDAs reduced growth of HL, in vitro, 72 h after treatment. The reduced cell growth of L428 was associated with modest increases in nuVDR in response to treatment with calcipotriol and EB1089.

In our study, the dose of VD3 (10 µM) used to elicit only modest decrease in cell growth is considered to be at supra-physiological concentration and this may be a consequence of low basal levels of VDR expression in unstimulated cells. In follicular low grade non-Hodgkin’s lymphoma (NHL), low levels of VDR expression was detected in primary tumor cells and cell lines (SU-DHL4 and SU-DUL5), however high concentration of VD3 was used to produce growth restriction in vitro [10]. In contrast, cellular models of acute myeloid leukemia (HL-60 cells) and diffuse large B cell lymphomas (DOHH2, K422) express high levels of VDR and display moderate cytotoxicity and pro-apoptotic responses upon exposure to nanomolar concentrations of VD3 (and VDAs) [11]. These observations suggest the levels of VDR expression in unstimulated cells may influence extent of VD3 sensitivity of some B malignancies. Additionally, while VD3 fail to stimulate nuVDR in our study (compare to DMSO), nanomolar concentrations of VD3 resulted in significantly higher nuVDR in other B cell neoplasms [11].

Because low VDR expression may hinder anti-tumor activities of VD3, it will be important to develop strategies to induce increased VDR expression. One of these approaches involved ligand-stimulated upregulation of receptor. It has been reported that VD3 stimulation resulted in the VDR upregulation [12, 13]. However, VD3-stimulated upregulation may not be possible in all types of VDR-positive neoplasms. Other approaches include the use of a non-vitamin inducer. Progesterone directly induced upregulation of VDR expression in T lymphocytes, via binding progesterone receptor-binding elements in the intron region after the first noncoding exon of the VDR gene [14]. In addition, progesterone enhanced the anti-tumor activities of VD3 by upregulating of VDR expression in endometrial cancer cells [15]. Inducer-stimulation of VDR expression may be useful for cancer therapy in which primary tumor cells exhibit low levels of VDR expression.

Application of supra-physiological concentration of VD3 to suppress tumor growth in vivo can promote hypercalcemia and hypercalciuria [16], leading to hardening of soft tissues. As a result, low-calcemic VDAs were developed [11, 17]. Two of these molecules, calcipotriol and EB1089 showed anti-tumor activities in a number of studies [18, 19]. However, EB1089 appeared to be amongst the most potent anti-tumor VDA [20]. In our study, treatment with either calcipotriol or EB1089 resulted in significant decrease in cell growth which also correlated with greater nuVDR. Future studies are warranted to determine the underlying mechanism(s) by which calcipotriol and EB1089 limit growth of HL.

Limitations

Our study has limitations that must be considered. A positive control such as the breast cancer cell line MCF7 or the myeloid leukemia cell HL-60, both of which previously showed significant sensitivities to VD3/VDAs were not included in our study. The current study also suffers from a lack of cell cycle analysis and other molecular details.

Notes

Authors’ contributions

RG conceptualized project, designed and conducted experiments, interpreted data and wrote manuscript. BZ, LV and MW conducted experiments, OO, JM, SR interpreted data. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank the CUNY Research Foundation for providing funding for this project.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Not applicable.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Funding

Support for this project was provided in part by a PSC-CUNY Award, jointly funded by The Professional Staff Congress and The City University of New York (Award #: TRADB-48-360), and The City University of New York Community College Research Grant (Award #: 80212-03-17). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Kulling PM, et al. Vitamin D in hematological disorders and malignancies. Eur J Haematol. 2017;98(3):187–97.CrossRefGoogle Scholar
  2. 2.
    Drake MT, et al. Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. J Clin Oncol. 2010;28(27):4191–8.CrossRefGoogle Scholar
  3. 3.
    Shui IM, et al. Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer. 2015;121(12):1949–56.CrossRefGoogle Scholar
  4. 4.
    Kim Y, Je Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. Br J Cancer. 2014;110(11):2772–84.CrossRefGoogle Scholar
  5. 5.
    Atoum M, Alzoughool F. Vitamin D and breast cancer: latest evidence and future steps. Breast Cancer. 2017;11:1178223417749816.PubMedGoogle Scholar
  6. 6.
    Samuel S, Sitrin MD. Vitamin D’s role in cell proliferation and differentiation. Nutr Rev. 2008;66(10 Suppl 2):S116–24.CrossRefGoogle Scholar
  7. 7.
    Renne C, Benz AH, Hansmann ML. Vitamin D3 receptor is highly expressed in Hodgkin’s lymphoma. BMC Cancer. 2012;12:215.CrossRefGoogle Scholar
  8. 8.
    Gharbaran R, et al. Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients. J Hematol Oncol. 2013;6:62.CrossRefGoogle Scholar
  9. 9.
    Consolini R, et al. Effects of vitamin D on the growth of normal and malignant B-cell progenitors. Clin Exp Immunol. 2001;126(2):214–9.CrossRefGoogle Scholar
  10. 10.
    Hickish T, et al. The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br J Cancer. 1993;68(4):668–72.CrossRefGoogle Scholar
  11. 11.
    Kozielewicz P, et al. Novel vitamin D analogues; cytotoxic and anti-proliferative activity against a diffuse large B-cell lymphoma cell line and B-cells from healthy donors. J Steroid Biochem Mol Biol. 2016;164:98–105.CrossRefGoogle Scholar
  12. 12.
    Provvedini DM, et al. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science. 1983;221(4616):1181–3.CrossRefGoogle Scholar
  13. 13.
    Solvsten H, et al. Upregulation of vitamin D receptor levels by 1,25(OH)2 vitamin D3 in cultured human keratinocytes. Arch Dermatol Res. 1997;289(6):367–72.CrossRefGoogle Scholar
  14. 14.
    Thangamani S, et al. Cutting edge: progesterone directly upregulates vitamin d receptor gene expression for efficient regulation of T cells by calcitriol. J Immunol. 2015;194(3):883–6.CrossRefGoogle Scholar
  15. 15.
    Lee LR, et al. Progesterone enhances calcitriol antitumor activity by upregulating vitamin D receptor expression and promoting apoptosis in endometrial cancer cells. Cancer Prev Res. 2013;6(7):731–43.CrossRefGoogle Scholar
  16. 16.
    Mocellin S. Vitamin D and cancer: deciphering the truth. Biochim Biophys Acta. 2011;1816(2):172–8.PubMedGoogle Scholar
  17. 17.
    Kragballe K. Vitamin D analogues in the treatment of psoriasis. J Cell Biochem. 1992;49(1):46–52.CrossRefGoogle Scholar
  18. 18.
    Emanuelsson I, et al. Vitamin D analogues tacalcitol and calcipotriol inhibit proliferation and migration of T98G human glioblastoma cells. Basic Clin Pharmacol Toxicol. 2018;123(2):130–6.CrossRefGoogle Scholar
  19. 19.
    Segovia-Mendoza M, et al. The addition of calcitriol or its synthetic analog EB1089 to lapatinib and neratinib treatment inhibits cell growth and promotes apoptosis in breast cancer cells. Am J Cancer Res. 2017;7(7):1486–500.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Hansen CM, et al. Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr Pharm Des. 2000;6(7):803–28.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Rajendra Gharbaran
    • 1
    • 2
    Email author
  • Bo Zhang
    • 2
  • Luis Valerio
    • 1
    • 2
  • Onyekwere Onwumere
    • 2
    • 3
  • Madeline Wong
    • 2
  • Jason Mighty
    • 2
    • 3
  • Stephen Redenti
    • 2
    • 3
  1. 1.Department of Biological SciencesBronx Community College, The City University of New YorkBronxUSA
  2. 2.Department of Biological SciencesLehman College, City University of New YorkBronxUSA
  3. 3.Biology Doctoral Program, The Graduate School and University CenterCity University of New YorkNew YorkUSA

Personalised recommendations